Canada-based DeCell Technologies announced plans to use an equity investment of approximately $239,000 to finish development and human testing of a product based on donated human skin that can treat diabetic foot ulcers, chronic wounds, burns and surgical wounds. When applied to wounds, the biological dressing promotes tissue regeneration.

Full Story:
Metro (Canada)

Related Summaries